Skin cancer – Malignant melanoma

Published on 05/03/2015 by admin

Filed under Dermatology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1506 times

Skin cancer – Malignant melanoma

Malignant melanoma is a malignant tumour of melanocytes, usually arising in the epidermis. It is the most lethal of the main skin tumours and has increased in incidence over the last three decades. The important pathogenic role of excessive ultraviolet (UV) radiation exposure has been the subject of public education campaigns. Genetics may be important, and up to 5% of patients have a family history of malignant melanoma.

Management

The primary treatment is narrow surgical excision followed by re-excision of the scar dependent upon Breslow thickness. In situ tumours require a 0.5-cm re-excision, those up to 1 mm thick require a 1-cm margin, those of 1–2 mm thickness need a 2-cm margin and thicker tumours require a 2–3-cm clearance. A skin graft may be necessary to close the defect. Regular follow-up is needed to detect any recurrence, of which there are three main types:

Routine sentinel node biopsy (p. 115) or elective lymph node dissection is not recommended as a standard procedure at present. Radiotherapy is of limited use. Interferon-alpha may increase survival in patients with tumours more than 1.5 mm thick. For metastatic disease, chemotherapy with dacarbazine is the current standard but has limited effectiveness and significant toxicity. New therapies including ipilimumab, a monoclonal antibody targeting the negative T cell regulator molecule, CTLA-4, has been shown to improve survival in advanced melanoma, and BRAF kinase inhibitors in BRAF mutated melanomas have shown promise.